Alzamend Neuro News - ALZN

Company Name	Stock Ticker Symbol	Market	Type
Alzamend Neuro Inc	ALZN	NASDAQ	Common Stock

	Price Change	Change Percent	Stock Price	Last Traded
	-0.0357	-3.34%	1.0343	12:32:37

Open Price	Low Price	High Price	Close Price	Prev Close
1.05	1.00	1.05		1.07

more quote information »

Recent News

Date	Time	Source	Heading
12/11/2023	9:23	IHNW	FeaturedAether Global Innovations Corp. Announces Non-Brokered Private Placement
12/11/2023	08:00	BW	Alzamend Neuro Receives FDA “Study May Proceed” Notification..
11/20/2023	08:00	BW	Alzamend Neuro Receives FDA “Study May Proceed” Notification..
11/16/2023	16:30	EDGAR2	Form 8-K - Current report
11/16/2023	08:00	BW	Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid..
11/13/2023	08:00	BW	Alzamend Neuro Submits IND Application for a Phase IIA..
10/30/2023	16:30	EDGAR2	Form 8-K - Current report
10/30/2023	08:00	BW	Alzamend Neuro Announces Reverse Stock Split
10/23/2023	08:00	BW	Alzamend Neuro Submits IND Application for a Phase IIA..
10/02/2023	08:00	BW	Alzamend Neuro Receives FDA “Study May Proceed” Notification..
9/29/2023	16:30	EDGAR2	Form 8-K - Current report
9/26/2023	18:01	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
9/22/2023	16:30	EDGAR2	Form 8-K - Current report
9/22/2023	08:00	BW	Alzamend Neuro Granted Extension by Nasdaq Panel to Regain..
9/13/2023	17:09	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
9/08/2023	17:05	EDGAR2	Form 424B5 - Prospectus [Rule 424(b)(5)]
9/08/2023	17:00	EDGAR2	Form 8-K - Current report
9/01/2023	16:30	EDGAR2	Form DEFA14A - Additional definitive proxy soliciting..
8/30/2023	08:00	BW	Alzamend Neuro Submits IND Application for Phase IIA..
8/24/2023	16:30	EDGAR2	Form DEF 14A - Other definitive proxy statements
8/16/2023	16:30	EDGAR2	Form 8-K - Current report
8/11/2023	00:15	EDGAR2	Form EFFECT - Notice of Effectiveness
8/10/2023	16:30	EDGAR2	Form PRE 14A - Other preliminary proxy statements
8/07/2023	16:30	EDGAR2	Form 8-K - Current report
8/02/2023	16:31	EDGAR2	Form S-3 - Registration statement under Securities Act of..
7/27/2023	16:56	EDGAR2	Form 10-K - Annual report [Section 13 and 15(d), not S-K..
6/22/2023	08:00	BW	Alzamend Neuro Announces Positive Phase IIA Clinical Trial..
6/13/2023	08:00	BW	Alzamend Neuro CEO Stephan Jackman to Participate on the..
4/04/2023	06:30	BW	Ault Alliance Announces Alzamend Neuro Has Initiated Its..
4/03/2023	09:35	BW	KILL Alzamend Neuro Receives FDA “Study May Proceed” Letter..
4/03/2023	08:50	BW	Alzamend Neuro Announces the Initiation of a Phase I/IIA..
4/03/2023	08:00	BW	Alzamend Neuro Receives FDA “Study May Proceed” Letter for..
3/22/2023	08:00	BW	Alzamend Neuro Announces Completion of Clinical Portion of..
3/16/2023	08:00	BW	Alzamend Neuro Reports Third Fiscal Quarter Financial..
1/26/2023	08:00	BW	Alzamend Neuro to Present at Sequire Biotechnology..
1/04/2023	08:00	BW	Alzamend Neuro Partners With Biorasi to Conduct a..
12/28/2022	08:00	BW	Alzamend Neuro Partners With the Miller School of Medicine,..